Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
MSH2
癌症研究
MLH1
作者
Thierry André,Kai-Keen Shiu,Tae Won Kim,Benny Vittrup Jensen,Lars Henrik Jensen,Cornelis J. A. Punt,Denis Smith,Rocio Garcia-Carbonero,Julia Alcaide,Peter Gibbs,Christelle De La Fouchardiere,Fernando Rivera,Elena Elez,Johanna C. Bendell,Dung T. Le,Takayuki Yoshino,Wen Yan Zhong,David R. Fogelman,Patricia Marinello,Luis A. Diaz
3500Background: In the phase III, randomized open-label KEYNOTE-177 (NCT02563002) study 1L pembrolizumab (pembro) versus chemotherapy (chemo) provided superior progression-free survival (PFS) at se...
PDF的下载单位、IP信息已删除
(2025-6-4)
嘻嘻哈哈
4星
渡人舟
Ray
huanhuanhuan
Yinxb
谢大喵
小马宝莉
152455
囧囧
学霸业
AN
诸葛明明
你嵙这个期刊没买
parantal
嘟嘟
loii
xing_xing
重要柠檬
学术文献互助
皖公网安备34019202002308
